Regenerative medicine specialist PharmaResearch announced on the 23rd that it has signed a license-in and supply agreement with clinical-stage biotech venture Connext for the new drug candidate “CNT201.”

CNT201 is a biopharmaceutical that is expected to expand into various indications in aesthetic treatments, including cellulite therapy, and in collagen fibrotic tissue–related diseases for which non-surgical treatment options are limited, such as Dupuytren’s contracture and Peyronie’s disease.

The product completed Phase 1 clinical trials with the U.S. Food and Drug Administration (FDA) last year and is currently in Phase 2 trials.

Through this agreement, PharmaResearch will lead indication development and global commercialization in the aesthetic field. The company plans to be responsible for CNT201’s commercialization, distribution, sales, and branding, while expanding its business portfolio to encompass both aesthetic and therapeutic areas. Connext will be responsible for clinical development and manufacturing related to CNT201’s therapeutic indications.

A PharmaResearch official stated, “Based on the research and development and global business capabilities accumulated in the regenerative medicine market, the company will actively support CNT201’s entry into domestic and overseas beauty and therapeutic markets, and provide more patients with treatment opportunities, focusing on areas with significant unmet needs.”

Lee Woo-jong, CEO of Connext, said, “CNT201 is a differentiated biopharmaceutical based on recombinant gene technology that can offer a meaningful treatment option in the global market,” adding, “In particular, as cellulite is an area that causes considerable discomfort and stress from the patient’s perspective, we will accelerate the development of a treatment backed by scientific evidence and clinical efficacy.”

Popular News